Terms: = Germ cell tumor AND ABL1, p150, 25, ENSG00000097007, P00519, v-abl, bcr/abl, JTK7, c-ABL, ABL, BCR-ABL AND Treatment
6962 results:
1. Risk factors, impact and treatment of postoperative lymphatic leakage in children with abdominal neuroblastoma operated on by laparotomy.
Feng J; Mou J; Yang S; Ren Q; Chang S; Yang W; Cheng H; Chang X; Zhu Z; Han J; Qin H; Wang H; Ni X
BMC Surg; 2024 May; 24(1):168. PubMed ID: 38811926
[TBL] [Abstract] [Full Text] [Related]
2. Beyond Clinical Trials: Understanding Neurotrophic Tropomyosin Receptor Kinase Inhibitor Challenges and Efficacy in Real-World Pediatric Oncology.
Vince CSC; Brassesco MS; Mançano BM; Gregianin LJ; Carbone EK; do Amaral E Castro A; Dwan VSY; Menezes da Silva RZ; Mariano CS; da Mata JF; Silva MO; Caran EMM; Macedo CD; Alves da Costa G; Esteves TC; Silva LN; Ferman SE; Martins FD; Cristófani LM; Odone-Filho V; Silva MM; Reis RM; Pianovski MAD; Campregher PV; Kunii MS; de Sá Rodrigues KE; Carvalho Filho NP; Valera ET;
JCO Precis Oncol; 2024 May; 8():e2300713. PubMed ID: 38810175
[TBL] [Abstract] [Full Text] [Related]
3. Navigating diagnostic challenges-distinguishing malignant melanoma and clear cell sarcoma of soft tissues: a case report and review of the literature.
Abdouh S; Boujguenna I; Soleh A; Abkari I; Rais H
J Med Case Rep; 2024 May; 18(1):249. PubMed ID: 38755643
[TBL] [Abstract] [Full Text] [Related]
4. Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial.
Raez LE; Kang H; Ohe Y; Khanal M; Han Y; Szymczak S; Barker SS; Gilligan AM
ESMO Open; 2024 May; 9(5):103444. PubMed ID: 38749381
[TBL] [Abstract] [Full Text] [Related]
5. First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study.
D'Angelo SP; Lebbé C; Mortier L; Brohl AS; Fazio N; Grob JJ; Prinzi N; Hanna GJ; Hassel JC; Kiecker F; von Heydebreck A; Güzel G; Nghiem P
ESMO Open; 2024 May; 9(5):103461. PubMed ID: 38744102
[TBL] [Abstract] [Full Text] [Related]
6. Efficacy and safety of high-dose chemotherapy as the first or subsequent salvage treatment line in patients with relapsed or refractory germ cell cancer: an international multicentric analysis.
Seidel C; Schaefers C; Connolly EA; Weickhardt A; Grimison P; Wong V; De Giorgi U; Hentrich M; Zschäbitz S; Ochsenreither S; Vincenzi B; Oing C; Bokemeyer C; Engel N; Alsdorf W; Tran B
ESMO Open; 2024 May; 9(5):103449. PubMed ID: 38744098
[TBL] [Abstract] [Full Text] [Related]
7. Sporadic subependymal giant cell astrocytoma with somatic
Alassiri AH; Alfayea TM; Aljared TI; Alenezi KR
Neurosciences (Riyadh); 2024 May; 29(2):139-143. PubMed ID: 38740392
[TBL] [Abstract] [Full Text] [Related]
8. Understanding supported self-management for people living with a lower-grade glioma: Implementation considerations through the lens of normalisation process theory.
Rimmer B; Finch T; Balla M; Dutton L; Williams S; Lewis J; Gallagher P; Burns R; Araújo-Soares V; Menger F; Sharp L;
Health Expect; 2024 Jun; 27(3):e14073. PubMed ID: 38733245
[TBL] [Abstract] [Full Text] [Related]
9. Repeat Radiosurgery for Sporadic Vestibular Schwannoma After Primary Radiosurgical Failure: An International Multi-institutional Investigation.
Khandalavala KR; Herberg HA; Kay-Rivest E; Moore LS; Yancey KL; Marinelli JP; Lund-Johansen M; Kosaraju N; Lohse CM; Kutz W; Santa Maria PL; Golfinos JG; Kondziolka D; Carlson ML; Tveiten ØV; Link MJ
Otol Neurotol; 2024 Jun; 45(5):587-593. PubMed ID: 38728563
[TBL] [Abstract] [Full Text] [Related]
10. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
Schadendorf D; Dummer R; Flaherty KT; Robert C; Arance A; de Groot JWB; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Yamazaki N; Queirolo P; Guenzel C; Polli A; Thakur M; di Pietro A; Ascierto PA
Eur J Cancer; 2024 Jun; 204():114073. PubMed ID: 38723373
[TBL] [Abstract] [Full Text] [Related]
11. Temozolomide resistance mechanisms: unveiling the role of translesion DNA polymerase kappa in glioblastoma spheroids in vitro.
Ribeiro DL; Latancia MT; de Souza I; Ariwoola AA; Mendes D; Rocha CRR; Lengert AVH; Menck CFM
Biosci Rep; 2024 May; 44(5):. PubMed ID: 38717250
[TBL] [Abstract] [Full Text] [Related]
12. Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.
Moser JC; Bhatia S; Amin A; Pavlick AC; Betts KA; Du EX; Poretta T; Shelley K; Srinivasan S; Sakkal LA; Palaia J; Lobo M; Pe Benito M; Linton JA; Chen Y; Xu C; Yin L; Sundar M; Weber J
Cancer Immunol Immunother; 2024 May; 73(7):116. PubMed ID: 38713408
[TBL] [Abstract] [Full Text] [Related]
13. Decoding the molecular landscape: A novel prognostic signature for uveal melanoma unveiled through programmed cell death-associated genes.
Liu Z; Yu L; Lai J; Zhang R
Medicine (Baltimore); 2024 May; 103(18):e38021. PubMed ID: 38701273
[TBL] [Abstract] [Full Text] [Related]
14. Characterizing the presentation, management, and clinical outcomes of patients with intradural spinal chordomas: a systematic review.
Saint-Germain MA; Kramer P; Weber-Levine C; Jiang K; Al-Mistarehi AH; Redmond KJ; Lee SH; Bettegowda C; Theodore N; Lubelski D
Neurosurg Focus; 2024 May; 56(5):E14. PubMed ID: 38691865
[TBL] [Abstract] [Full Text] [Related]
15. Optimizing radiotherapy strategies for skull base chordoma: a comprehensive meta-analysis and systematic review of treatment modalities and outcomes.
Palavani LB; Borges P; Andreão FF; Borges J; Batista S; Oliveira LB; Ferreira MY; Reis PCA; Pontes J; Negri H; Beer-Furlan A; Krishna C; Bertani R; Rassi MS
Neurosurg Focus; 2024 May; 56(5):E11. PubMed ID: 38691862
[TBL] [Abstract] [Full Text] [Related]
16. Supramarginal resection of skull base chordomas: proof of concept and preliminary outcomes.
Rychen J; Constanzo F; Xu Y; Johnstone TM; Bex A; Rinaldi M; Lee CK; Fernandez-Miranda JC
Neurosurg Focus; 2024 May; 56(5):E3. PubMed ID: 38691859
[TBL] [Abstract] [Full Text] [Related]
17. Quality of life in chordoma survivors: results from the Chordoma Foundation Survivorship Survey.
Jimenez AE; Cicalese KV; Jimenez MA; Chakravarti S; Kuo CC; Lozinsky S; Schwab JH; Knowlton SE; Rowan NR; Mukherjee D
Neurosurg Focus; 2024 May; 56(5):E12. PubMed ID: 38691854
[TBL] [Abstract] [Full Text] [Related]
18. Long-term outcome of primary clival chordomas: a single-center retrospective study with an emphasis on the timing of recurrences based on the primary treatment.
Hong S; Shinya Y; Mahajan A; Laack NN; O'Brien EK; Stokken JK; Janus JR; Raghunathan A; Link MJ; Van Gompel JJ
Neurosurg Focus; 2024 May; 56(5):E4. PubMed ID: 38691852
[TBL] [Abstract] [Full Text] [Related]
19. Efficacy and safety of neoadjuvant therapy in gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.
Yan Y; Wu D; Wang W; Lv Y; Yang L; Liu Y; Dong P; Yu X
J Cancer Res Ther; 2024 Apr; 20(2):633-641. PubMed ID: 38687934
[TBL] [Abstract] [Full Text] [Related]
20. D-Loop Mutations as Prognostic Markers in Glioblastoma-A Pilot Study.
Szmyd B; Stanisławska P; Podstawka M; Zaczkowski K; Izbiński PM; Kulczycka-Wojdala D; Stawski R; Wiśniewski K; Janczar K; Braun M; Białasiewicz P; Jaskólski DJ; Bobeff EJ
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673919
[TBL] [Abstract] [Full Text] [Related]
[Next]
